← All trials
NCT06019130
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 10, 2023
- Primary completion
- Jan 9, 2026
- Completion date
- Jan 9, 2028
- First posted
- Aug 31, 2023
- Last posted
- May 16, 2024
- Enrollment
- 57
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- German Society for Pediatric Oncology and Hematology GPOH gGmbHLead sponsor
- Deutsche Krebshilfe e.V.Collaborator
- RWTH Aachen UniversitySponsor investigator
- RWTH Aachen UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.